At Catalina Eye Care, we’re proud to offer Valeda® Photobiomodulation (PBM) — an advanced, non-invasive red light therapy for patients in Tucson, AZ living with early and intermediate dry age-related macular degeneration (AMD). The Valeda® Light Delivery System is the first and only treatment authorized by the U.S. Food and Drug Administration for this stage of dry AMD, giving patients a proactive option to help protect their sight before advanced vision loss occurs. Whether you’ve recently been diagnosed or have a family history of AMD, our team is here to guide you through every step of the process.
Authorized by the FDA on November 4, 2024, Valeda delivers an in-office therapy called photobiomodulation (PBM) — also known as red light therapy — that uses precise wavelengths of light to support the health of retinal cells. Valeda delivers three carefully selected wavelengths — amber (590 nm), red (660 nm), and near-infrared (850 nm) — to the eye through Light Emitting Diodes (LEDs). It is important to understand that Valeda is not a laser. The LEDs are very low-powered, do not cause heat damage to the eye, and have been shown to be safe and well-tolerated. The device has been used in Europe since 2019, with more than 800,000 treatments performed worldwide.
Dry AMD damages the cells of the macula, the central part of the retina responsible for sharp, detailed vision. As these cells become less efficient, vision gradually declines. Valeda PBM works at the cellular level by activating cytochrome c oxidase, an essential component of the mitochondria. This stimulation enhances the production of adenosine triphosphate (ATP) — the cell’s primary source of energy — while improving local oxygenation, encouraging vasodilation, and helping reduce the chronic inflammation that contributes to disease progression. The result is healthier retinal cells better equipped to maintain or recover function.
Located conveniently in Tucson and Oro Valley, AZ, Catalina Eye Care combines advanced technology with experienced, patient-centered care. We pride ourselves on delivering personalized treatment plans designed to protect your long-term vision.
The Valeda Light Delivery System is indicated for patients with best-corrected visual acuity (BCVA) between 20/32 and 20/70 who have dry AMD characterized by at least three medium drusen (greater than 63 µm and up to 125 µm in diameter), large drusen (greater than 125 µm in diameter), or non-central geographic atrophy — and the absence of neovascular (wet) maculopathy or center-involving geographic atrophy. This makes Valeda especially valuable for patients in the early and intermediate stages of dry AMD, a population that historically had no approved treatment options.
Patients should not receive Valeda if they have a known photosensitivity to yellow, red, or near-infrared light; a history of light-activated central nervous system disorders such as epilepsy or migraine; or if they have used photosensitizing medications within the past 30 days. Your provider at Catalina Eye Care will determine whether Valeda is the right option for you.
Valeda PBM is one of the most patient-friendly treatments in modern retinal care. There are no injections, no anesthesia, no eye dilation, and no speculum. The device looks similar to those used for routine vision testing. Each session takes approximately four minutes per eye (under ten minutes total for both eyes) and is completely painless. A standard course consists of nine sessions administered three times per week over a three- to five-week period. There is no recovery time, and most patients return to normal activities immediately.
The safety and effectiveness of Valeda PBM have been studied extensively in the LIGHTSITE I, II, and III clinical trials. In the pivotal LIGHTSITE III study — a 24-month, multicenter, randomized, sham-controlled trial — patients treated with Valeda gained an average of approximately one line of visual acuity (ETDRS) compared to baseline at both 13 and 21 months, with the benefit maintained at month 24. Approximately 64% of PBM-treated eyes gained at least one line of vision at month 24 compared to baseline. The trial also showed reduced drusen volume and significantly slower progression to geographic atrophy in treated eyes versus the sham group.
Because Valeda is non-invasive, there is no downtime. After each session you can expect to:
Valeda Photobiomodulation received FDA authorization in November 2024, and Medicare now provides coverage for eligible patients. Our team will gladly verify your benefits before treatment and give you a clear, written breakdown of any remaining out-of-pocket cost, so you can begin with full confidence in both your care and your costs.
Until the introduction of Valeda PBM, patients diagnosed with early or intermediate dry AMD had no approved treatment to slow disease progression or improve vision — treatment was typically delayed until the disease advanced and irreversible vision loss had already occurred. Valeda changes that paradigm. By intervening earlier, before significant damage to the macula develops, patients have the opportunity to maintain better visual function for longer and potentially delay or avoid progression to advanced stages of AMD. At Catalina Eye Care, we’re committed to bringing the Tucson and Oro Valley communities the latest proven advances in retinal care.
If you’ve been diagnosed with dry age-related macular degeneration, or you have a family history of AMD and want to learn more about your options, the team at Catalina Eye Care can help. Don’t wait to protect your vision — contact us today to schedule your Valeda PBM consultation in Tucson, AZ.
No. Valeda uses low-powered Light Emitting Diodes (LEDs), not a laser. The light does not cause heat damage to the eye and has been shown to be safe and well-tolerated.
No. Valeda PBM is completely painless. There are no injections, no anesthesia, and no eye dilation. More than 97% of patients in clinical trials reported no pain or discomfort during treatment.
A standard course consists of nine sessions given three times per week over a three- to five-week period. To maintain the benefits, the series is typically repeated every four to six months.
Valeda is intended for patients with early or intermediate dry AMD who meet specific vision and retinal criteria. The best way to find out if you’re a candidate is to schedule an evaluation with our team at Catalina Eye Care.
Medicare now provides coverage for eligible patients, and our team will gladly verify your benefits before treatment.
Catalina Eye Care offers Valeda® PBM in Tucson, AZ — the first FDA-authorized red light therapy for early and intermediate dry age-related macular degeneration (AMD).
EVO ICL is an advanced vision correction procedure designed to reduce or eliminate the need for glasses or contact lenses. Unlike LASIK, which reshapes the cornea, EVO ICL works by placing a tiny, biocompatible lens inside the eye to correct vision.
